Chemocentryx Inc (CCXI) 7.85 $CCXI
Primary Sclerosing Cholangitis Therapeutic Pipeline Review H1 2015 Market Research Report at RnRMarketResearch.com
PRWeb - Fri Jan 30, 3:30PM CST
The report "Primary Sclerosing Cholangitis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Primary Sclerosing Cholangitis. Primary sclerosing cholangitis is a liver disease in which the bile ducts gradually decrease in size due to swelling and scarring. Different treatments are available to control symptoms that may develop and also to manage any complications which may occur. Many people with primary sclerosing cholangitis do not get symptoms, especially in the early stages of the disease. The most common symptoms are fatigue, pruritus, jaundice and yellowing of the skin and eyes. The symptoms of this disease can be treated with antibiotics, vitamins and medications to control itching, improve bile flow etc. Complete Report is Available at http://www.rnrmarketresearch.com/primary-scle...eport.html.
GILD: 101.90 (+1.10), CCXI: 7.85 (+0.04), ICPT: 209.12 (+7.12)
Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 30, 3:00PM CST
BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), PCYC: 163.28 (+0.23), ZSPH: 46.77 (+3.42), RMTI: 11.17 (+0.15), BCLI: 3.86 (-0.02), SIEN: 15.90 (+0.38), JNJ: 99.62 (+1.18), ECYT: 5.26 (-0.02), SNY: 49.42 (+0.82), LENS: 6.00 (-0.67), REGN: 402.40 (+0.66), SYK: 94.51 (+1.14), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), AMGN: 153.48 (+0.30), APPY: 0.45 (-0.01), MNKD: 7.00 (+0.02), CELG: 115.88 (+0.16), ISRG: 510.73 (+3.02), GILD: 101.90 (+1.10), ANIP: 62.69 (-0.43), MRK: 58.81 (-0.07), ALXN: 182.29 (+6.02), CCXI: 7.85 (+0.04), ICPT: 209.12 (+7.12), AEZS: 0.53 (unch), ATRS: 2.45 (+0.05), NASH: 31.48 (+0.01)
Playing Chemocentryx Against Alexion: Opportunity For Asymmetric Return
Kanak Kanti De - at Seeking Alpha - Wed Jan 28, 2:10PM CST
CCXI: 7.85 (+0.04), ALXN: 182.29 (+6.02)
ChemoCentryx to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Tue Jan 06, 7:30AM CST
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 33 Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015, at 4:00 p.m. Pacific Time. The conference will be held at the Westin St. Francis Hotel in San Francisco, CA.
JPM: 59.67 (+0.10), CCXI: 7.85 (+0.04)
Biotech Stock Roundup: Sophiris & Cyclacel Plunge on Data, ChemoCentryx Gains on Positive Results - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 17, 9:26AM CST
It has been a relatively quiet week with the holiday season coming up though a few companies came out with important pipeline updates.
CYCC: 0.62 (-0.01), CBST: 101.94 (+0.14), SPHS: 0.44 (-0.01), CCXI: 7.85 (+0.04), ALXN: 182.29 (+6.02), EXEL: 2.48 (+0.20)
ChemoCentryx Up on Positive Diabetic Nephropathy Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 5:45PM CST
ChemoCentryx, Inc., announced positive top-line 52-week data from its phase II study on its candidate CCX140 for diabetic nephropathy.
ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), SCMP: 15.32 (+0.04), CCXI: 7.85 (+0.04)
Can The Uptrend Continue for ChemoCentryx (CCXI)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 10:22AM CST
Can The Uptrend Continue for ChemoCentryx (CCXI)?
CCXI: 7.85 (+0.04)
ChemoCentryx (CCXI) Shows Strength: Stock Moves Up 24.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 7:51AM CST
ChemoCentryx, Inc. (CCXI) was a big mover last session, as its shares rose almost 25% on the day.
LCI: 57.78 (-0.91), SCMP: 15.32 (+0.04), CCXI: 7.85 (+0.04), IG: 10.57 (-0.12)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 4:39PM CST
ENPH: 15.15 (+0.37), ATTO: 11.72 (-0.21), TVIX: 2.57 (-0.05), GGB: 3.59 (+0.09), ARRS: 26.68 (+0.41), DGAZ: 7.10 (-0.49), SGMO: 15.40 (+0.14), CCXI: 7.85 (+0.04), ILF: 31.60 (+0.44), GSAT: 2.40 (+0.08)
Why ChemoCentryx Inc's Shares Shot 60% Higher Today
Alex Planes, The Motley Fool - Motley Fool - Fri Dec 12, 12:02PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ChemoCentryx have gained more than 60% as...
CCXI: 7.85 (+0.04)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 11:46AM CST
ESL: 115.76 (+0.80), CGA: 2.02 (+0.09), FRO: 2.96 (+0.07), RTK: 1.26 (+0.04), TLM: 7.63 (-0.03), MILL: 2.07 (+0.09), ZQK: 2.26 (+0.05), EOX: 1.15 (unch), HGSH: 3.05 (-0.13), ISIG: 3.19 (unch), DRL: 2.31 (+0.10), EROC: 2.63 (+0.15), SSTK: 56.49 (-2.75), CISG: 8.00 (-0.06), SOFO: 8.07 (-0.16), CELP: 16.38 (+0.15), CCXI: 7.85 (+0.04), MPO: 1.00 (-0.02), NAO: 9.84 (+0.46), VNR: 18.09 (+0.38)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 8:16AM CST
FRO: 2.96 (+0.07), GDP: 3.58 (+0.29), TLM: 7.63 (-0.03), ONVO: 6.34 (+0.07), EOX: 1.15 (unch), CCXI: 7.85 (+0.04), HCCI: 12.05 (-0.14), ONTY: 1.57 (unch), ADBE: 76.51 (+1.92)
ChemoCentryx soars on Phase 2 results
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 7:56AM CST
CCXI: 7.85 (+0.04)
ChemoCentryx Announces Positive Results in Phase II Diabetic Nephropathy Trial With CCR2 Inhibitor CCX140
GlobeNewswire - Fri Dec 12, 5:30AM CST
Primary Endpoint Achieved; Statistically Significant Reduction in Urinary Protein Over 52 Weeks
CCXI: 7.85 (+0.04)
Fatty Liver Disease - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/7dx4sz/fatty_liver) has announced the addition of the "Fatty Liver Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fatty Liver Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fatty Liver Disease and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Fatty Liver Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Fatty Liver Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - GW Pharmaceuticals plc - Protalix BioTherapeutics, Inc. - Genovate Biotechnology Co., LTD. - Huons Co., Ltd. - ChemoCentryx, Inc. - ACROVIS biostructures GmbH - Generon (Shanghai) Corporation Ltd. For more information visit http://www.researchandmarkets.com/research/7d...atty_liver
CCXI: 7.85 (+0.04)
ChemoCentryx to Host Conference Call on Friday, December 12, 2014 to Discuss Top-Line Phase II Results in Patients With Diabetic Nephropathy With CCX140, an Orally Administered CCR2 Inhibitor
GlobeNewswire - Thu Dec 11, 3:30PM CST
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, today announced that it will host a conference call and webcast on Friday, December 12, 2014 at 8:30 a.m. Eastern Time (ET) to present top-line results from its Phase II trial with CCX140, an inhibitor of the chemokine receptor known as CCR2, in patients with diabetic nephropathy.
CCXI: 7.85 (+0.04)
ChemoCentryx: Can It Break Into The Soliris Market?
Kanak Kanti De - at Seeking Alpha - Thu Dec 11, 2:08PM CST
ALXN: 182.29 (+6.02), CCXI: 7.85 (+0.04)
ChemoCentryx (CCXI) Shows Strength: Stock Moves Up 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 8:39AM CST
ChemoCentryx, Inc. (CCXI) was a big mover last session, as its shares rose almost 6% on the day.
LCI: 57.78 (-0.91), SCMP: 15.32 (+0.04), CCXI: 7.85 (+0.04), IG: 10.57 (-0.12)
ChemoCentryx Drug Gets Orphan Designation in Europe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 5:07PM CST
Positive news flowed in for ChemoCentryx, Inc., (CCXI) when it announced that the European Commission has granted orphan medicinal product designation to its pipeline candidate CCX168.
VRX: 167.00 (-0.50), ARQL: 1.35 (+0.04), SCMP: 15.32 (+0.04), CCXI: 7.85 (+0.04)
ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis
GlobeNewswire - Thu Dec 04, 7:30AM CST
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, reported today that the European Commission has granted orphan medicinal product designation for CCX168, an orally administered inhibitor targeting the receptor for the complement protein known as C5a (C5aR), for the treatment of microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) (formerly known as Wegener's Granulomatosis, or WG). Both conditions are forms of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV).
CCXI: 7.85 (+0.04)
Primary Sclerosing Cholangitis Therapeutic Pipeline Review H1 2015 Market Research Report at RnRMarketResearch.com
PRWeb - Fri Jan 30, 3:30PM CST
The report "Primary Sclerosing Cholangitis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Primary Sclerosing Cholangitis. Primary sclerosing cholangitis is a liver disease in which the bile ducts gradually decrease in size due to swelling and scarring. Different treatments are available to control symptoms that may develop and also to manage any complications which may occur. Many people with primary sclerosing cholangitis do not get symptoms, especially in the early stages of the disease. The most common symptoms are fatigue, pruritus, jaundice and yellowing of the skin and eyes. The symptoms of this disease can be treated with antibiotics, vitamins and medications to control itching, improve bile flow etc. Complete Report is Available at http://www.rnrmarketresearch.com/primary-scle...eport.html.
GILD: 101.90 (+1.10), CCXI: 7.85 (+0.04), ICPT: 209.12 (+7.12)
Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 30, 3:00PM CST
BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), PCYC: 163.28 (+0.23), ZSPH: 46.77 (+3.42), RMTI: 11.17 (+0.15), BCLI: 3.86 (-0.02), SIEN: 15.90 (+0.38), JNJ: 99.62 (+1.18), ECYT: 5.26 (-0.02), SNY: 49.42 (+0.82), LENS: 6.00 (-0.67), REGN: 402.40 (+0.66), SYK: 94.51 (+1.14), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), AMGN: 153.48 (+0.30), APPY: 0.45 (-0.01), MNKD: 7.00 (+0.02), CELG: 115.88 (+0.16), ISRG: 510.73 (+3.02), GILD: 101.90 (+1.10), ANIP: 62.69 (-0.43), MRK: 58.81 (-0.07), ALXN: 182.29 (+6.02), CCXI: 7.85 (+0.04), ICPT: 209.12 (+7.12), AEZS: 0.53 (unch), ATRS: 2.45 (+0.05), NASH: 31.48 (+0.01)
Playing Chemocentryx Against Alexion: Opportunity For Asymmetric Return
Kanak Kanti De - at Seeking Alpha - Wed Jan 28, 2:10PM CST
CCXI: 7.85 (+0.04), ALXN: 182.29 (+6.02)
ChemoCentryx to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Tue Jan 06, 7:30AM CST
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 33 Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015, at 4:00 p.m. Pacific Time. The conference will be held at the Westin St. Francis Hotel in San Francisco, CA.
JPM: 59.67 (+0.10), CCXI: 7.85 (+0.04)
Biotech Stock Roundup: Sophiris & Cyclacel Plunge on Data, ChemoCentryx Gains on Positive Results - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 17, 9:26AM CST
It has been a relatively quiet week with the holiday season coming up though a few companies came out with important pipeline updates.
CYCC: 0.62 (-0.01), CBST: 101.94 (+0.14), SPHS: 0.44 (-0.01), CCXI: 7.85 (+0.04), ALXN: 182.29 (+6.02), EXEL: 2.48 (+0.20)
ChemoCentryx Up on Positive Diabetic Nephropathy Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 5:45PM CST
ChemoCentryx, Inc., announced positive top-line 52-week data from its phase II study on its candidate CCX140 for diabetic nephropathy.
ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), SCMP: 15.32 (+0.04), CCXI: 7.85 (+0.04)
Can The Uptrend Continue for ChemoCentryx (CCXI)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 10:22AM CST
Can The Uptrend Continue for ChemoCentryx (CCXI)?
CCXI: 7.85 (+0.04)
ChemoCentryx (CCXI) Shows Strength: Stock Moves Up 24.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 7:51AM CST
ChemoCentryx, Inc. (CCXI) was a big mover last session, as its shares rose almost 25% on the day.
LCI: 57.78 (-0.91), SCMP: 15.32 (+0.04), CCXI: 7.85 (+0.04), IG: 10.57 (-0.12)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 4:39PM CST
ENPH: 15.15 (+0.37), ATTO: 11.72 (-0.21), TVIX: 2.57 (-0.05), GGB: 3.59 (+0.09), ARRS: 26.68 (+0.41), DGAZ: 7.10 (-0.49), SGMO: 15.40 (+0.14), CCXI: 7.85 (+0.04), ILF: 31.60 (+0.44), GSAT: 2.40 (+0.08)
Why ChemoCentryx Inc's Shares Shot 60% Higher Today
Alex Planes, The Motley Fool - Motley Fool - Fri Dec 12, 12:02PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ChemoCentryx have gained more than 60% as...
CCXI: 7.85 (+0.04)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 11:46AM CST
ESL: 115.76 (+0.80), CGA: 2.02 (+0.09), FRO: 2.96 (+0.07), RTK: 1.26 (+0.04), TLM: 7.63 (-0.03), MILL: 2.07 (+0.09), ZQK: 2.26 (+0.05), EOX: 1.15 (unch), HGSH: 3.05 (-0.13), ISIG: 3.19 (unch), DRL: 2.31 (+0.10), EROC: 2.63 (+0.15), SSTK: 56.49 (-2.75), CISG: 8.00 (-0.06), SOFO: 8.07 (-0.16), CELP: 16.38 (+0.15), CCXI: 7.85 (+0.04), MPO: 1.00 (-0.02), NAO: 9.84 (+0.46), VNR: 18.09 (+0.38)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 8:16AM CST
FRO: 2.96 (+0.07), GDP: 3.58 (+0.29), TLM: 7.63 (-0.03), ONVO: 6.34 (+0.07), EOX: 1.15 (unch), CCXI: 7.85 (+0.04), HCCI: 12.05 (-0.14), ONTY: 1.57 (unch), ADBE: 76.51 (+1.92)
ChemoCentryx soars on Phase 2 results
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 7:56AM CST
CCXI: 7.85 (+0.04)
ChemoCentryx Announces Positive Results in Phase II Diabetic Nephropathy Trial With CCR2 Inhibitor CCX140
GlobeNewswire - Fri Dec 12, 5:30AM CST
Primary Endpoint Achieved; Statistically Significant Reduction in Urinary Protein Over 52 Weeks
CCXI: 7.85 (+0.04)
Fatty Liver Disease - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/7dx4sz/fatty_liver) has announced the addition of the "Fatty Liver Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fatty Liver Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fatty Liver Disease and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Fatty Liver Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Fatty Liver Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - GW Pharmaceuticals plc - Protalix BioTherapeutics, Inc. - Genovate Biotechnology Co., LTD. - Huons Co., Ltd. - ChemoCentryx, Inc. - ACROVIS biostructures GmbH - Generon (Shanghai) Corporation Ltd. For more information visit http://www.researchandmarkets.com/research/7d...atty_liver
CCXI: 7.85 (+0.04)
ChemoCentryx to Host Conference Call on Friday, December 12, 2014 to Discuss Top-Line Phase II Results in Patients With Diabetic Nephropathy With CCX140, an Orally Administered CCR2 Inhibitor
GlobeNewswire - Thu Dec 11, 3:30PM CST
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, today announced that it will host a conference call and webcast on Friday, December 12, 2014 at 8:30 a.m. Eastern Time (ET) to present top-line results from its Phase II trial with CCX140, an inhibitor of the chemokine receptor known as CCR2, in patients with diabetic nephropathy.
CCXI: 7.85 (+0.04)
ChemoCentryx: Can It Break Into The Soliris Market?
Kanak Kanti De - at Seeking Alpha - Thu Dec 11, 2:08PM CST
ALXN: 182.29 (+6.02), CCXI: 7.85 (+0.04)
ChemoCentryx (CCXI) Shows Strength: Stock Moves Up 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 8:39AM CST
ChemoCentryx, Inc. (CCXI) was a big mover last session, as its shares rose almost 6% on the day.
LCI: 57.78 (-0.91), SCMP: 15.32 (+0.04), CCXI: 7.85 (+0.04), IG: 10.57 (-0.12)
ChemoCentryx Drug Gets Orphan Designation in Europe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 5:07PM CST
Positive news flowed in for ChemoCentryx, Inc., (CCXI) when it announced that the European Commission has granted orphan medicinal product designation to its pipeline candidate CCX168.
VRX: 167.00 (-0.50), ARQL: 1.35 (+0.04), SCMP: 15.32 (+0.04), CCXI: 7.85 (+0.04)
ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis
GlobeNewswire - Thu Dec 04, 7:30AM CST
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, reported today that the European Commission has granted orphan medicinal product designation for CCX168, an orally administered inhibitor targeting the receptor for the complement protein known as C5a (C5aR), for the treatment of microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) (formerly known as Wegener's Granulomatosis, or WG). Both conditions are forms of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV).
CCXI: 7.85 (+0.04)
